Karabacak 2004.

Methods	RCT Setting: Turkey, single centre Number of participants randomised: 16
Participants	Summary: PCOS PCOS diagnostic criteria: observance of polycystic ovaries by transvaginal ultrasound examination performed during the first days of menstruation; oligo/amenorrhoea (intermenstrual interval ≥ 36) and hirsutism (Ferriman‐Gallwey score ≥ 7); with or without raised serum testosterone level Inclusion criteria: PCOS Exclusion criteria: did not mention in the article. The authors had been contacted, but no reply Baseline characteristics: the sibutramine group and the fluoxetine group are comparable in age, BMI, FSH, LH, androstenedione, free testosterone, insulin Reasons for withdrawals: not applicable. All participants completed the study and were included in the analysis
Interventions	Treatment: sibutramine 10 mg/day Control: fluoxetine 20 mg/day Duration: 10 days Co‐interventions: no
Outcomes	Endocrine factors: FSH (mIU/L), LH (mIU/L), LH/FSH ratio Metabolic factors: insulin (μIU/mL), glucose (mmol/L), leptin (ng/mL)
Notes	‐
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Did not describe in the article. The authors had been contacted, but no reply
Allocation concealment (selection bias)	Unclear risk	Did not describe in the article. The authors had been contacted, but no reply
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Does not state how many women were analysed
Selective reporting (reporting bias)	Unclear risk	Adverse events not reported
Other bias	Low risk	None detected
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Did not describe in the article. The authors had been contacted, but no reply
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Did not describe in the article. The authors had been contacted, but no reply

BMI: body mass index; FSH: follicle‐stimulating hormone; LH: luteinising hormone; PCOS: polycystic ovary syndrome; RCT: randomised controlled trial.